Literature DB >> 1453329

Inhibition of HIV-1 RNA production by the diphtheria toxin-related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2.

L Zhang1, C Waters, J Nichols, C Crumpacker.   

Abstract

Productive infection of cells by human immunodeficiency virus type 1 (HIV-1) is associated with the activation state of the cell and its obligatory expression of the interleukin-2 receptor (IL-2R), the latter providing a new target for antiviral therapy. A quantitative RNA-RNA hybridization assay is employed to detect production of HIV-1 RNA and to show that two IL-2 diphtheria toxin-related fusion proteins (DAB486IL-2 and its more potent, truncated form DAB389IL-2) inhibit HIV-1 RNA production in infected cells. A mutant form of DAB486IL-2 containing a single point mutation that inactivates the adenosine diphosphate ribosyltransferase activity of the toxin does not inhibit HIV RNA production, even though the molecule binds to the IL-2R. The active fusion proteins inhibit viral RNA replication in cells infected with HIV-1 clinical isolates as well as with a ZDV-resistant strain of HIV-1. These results indicate that IL-2 receptor-targeted fusion proteins can be utilized to inhibit HIV-1 replication effectively in infected human lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1453329

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  6 in total

1.  Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review.

Authors:  Bryan P Irish; Zafar K Khan; Pooja Jain; Michael R Nonnemacher; Vanessa Pirrone; Saifur Rahman; Nirmala Rajagopalan; Joyce B Suchitra; Kate Mostoller; Brian Wigdahl
Journal:  Am J Infect Dis       Date:  2009-07-01

2.  Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.

Authors:  J L Zhang; P L Sharma; C J Li; B J Dezube; A B Pardee; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

Review 4.  Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement.

Authors:  A Kinter; A S Fauci
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 5.  Eradication of HIV and Cure of AIDS, Now and How?

Authors:  Jielin Zhang; Clyde Crumpacker
Journal:  Front Immunol       Date:  2013-10-18       Impact factor: 7.561

Review 6.  Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.

Authors:  Jeffrey C Umotoy; Steven W de Taeye
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.